ACI Worldwide and Ingo Payments to Power Faster, Flexible Digital Disbursements

ACI Worldwide and Ingo Payments to Power Faster, Flexible Digital Disbursements

New ACI Speedpay Digital Disbursements solution boosts consumers’ financial autonomy

OMAHA, Neb.–(BUSINESS WIRE)–ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, and Ingo Payments, a leading provider of embedded banking and money mobility solutions, today announced a partnership to provide a flexible, fast and secure digital disbursements solution: ACI Speedpay Digital Disbursements. This new solution is a value-added feature as part of the ACI Speedpay platform to help businesses scale their disbursement operations efficiently to meet customer expectations and evolving regulatory standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318775347/en/

Ingo Payments

Ingo Payments

Many businesses today still rely on paper checks to disburse funds. However, according to the ACI Speedpay Pulse 2024 Report, consumer preference for digital payment channels is trending upward, with more than 75% of Americans preferring digital transactions. Digital payment accelerates disbursements, ensuring that consumers receive funds swiftly, especially during times of financial need. For example, timely and efficient insurance claim payouts after a natural disaster provide financial reprieve, reduce stress and strengthen customer loyalty.

With the new partnership, ACI and Ingo will provide flexible integration solutions that cater to the diverse needs of business customers, whether they require embedded payment capabilities or fully hosted SaaS-based disbursement experiences. The solution will support a range of disbursement options, including point-in-time disbursements, batch-based disbursements and real-time digital disbursements.

ACI Speedpay Digital Disbursements enables businesses to offer multiple payout options, including real-time payments, PayPal/Venmo, signature debit, and ACH. Businesses can streamline reporting and reconciliation by eliminating the delays associated with check deposits, reducing administrative overhead and improving cash flow efficiency.

“At ACI Speedpay, we like to say – life is hard enough, let’s make bill pay easy – the same can be said for disbursements, where consumers need their money fast and sent via their preferred payment type,” said Ron Shultz, General Manager of ACI Speedpay. “Our partnership with Ingo Payments enables ACI’s biller clients to offer numerous digital disbursement options to their consumers, serving to enhance the overall customer experience.”

“We’re proud to collaborate with ACI to provide businesses with seamless, scalable disbursement solutions that meet the evolving needs of today’s digital economy,” said Drew Edwards, CEO at Ingo Payments. “Together, we’re helping clients move money with greater speed, security and efficiency.”

About ACI Worldwide

ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and merchants can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With nearly 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities.

© Copyright ACI Worldwide, Inc. 2025

ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties’ trademarks referenced are the property of their respective owners.

About Ingo Payments

Ingo Payments empowers banks, fintechs, and enterprises to deliver modern financial experiences through its full-service embedded banking platform. Ingo’s bank-grade modern money stack, built with embedded compliance and risk management, enables seamless account funding, transfers, mobile deposits, payouts, digital wallets, account and card issuing, PFM, and rewards solutions across a wide range of industries and use cases. With a vertically integrated platform, Ingo helps clients minimize third-party risk, reduce operational complexity, and lower costs—all while accelerating go-to-market timelines. Learn more at ingopayments.com.

Media Contacts

ACI Worldwide

Nick Karoglou | Head of Communications and Corporate Affairs | [email protected]

Lyn Kwek | Communications and Corporate Affairs Director | [email protected]

Ingo Payments

Sarah Higgins

[email protected]

KEYWORDS: United States North America Nebraska

INDUSTRY KEYWORDS: Software Payments Banking Professional Services Technology Apps/Applications Digital Cash Management/Digital Assets Mobile/Wireless

MEDIA:

Logo
Logo
Photo
Photo
Ingo Payments

Cognyte Appoints Distinguished Innovator Ronny Lempel as Chief Technology Officer to Guide AI-Focused Research

Cognyte Appoints Distinguished Innovator Ronny Lempel as Chief Technology Officer to Guide AI-Focused Research

25+ years of technology expertise and leadership will continue to cultivate innovation for sustained company growth

HERZLIYA, Israel–(BUSINESS WIRE)–Cognyte Software Ltd. (NASDAQ: CGNT) (“Cognyte”), a global leader in investigative analytics software, today announced the appointment of Dr. Ronny Lempel as Chief Technology Officer (CTO). In this role, Lempel will apply over 25 years of proven, cross-discipline technology expertise to extend Cognyte’s innovation leadership and bring unparalleled vision and value to Cognyte’s customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318301357/en/

Cognyte appointed Dr. Ronny Lempel as Chief Technology Officer (CTO) to guide AI-focused research. In this role, Lempel will apply more than 25 years of proven, cross-discipline technology expertise to extend Cognyte’s innovation leadership and bring unparalleled vision and value to Cognyte’s customers.

Cognyte appointed Dr. Ronny Lempel as Chief Technology Officer (CTO) to guide AI-focused research. In this role, Lempel will apply more than 25 years of proven, cross-discipline technology expertise to extend Cognyte’s innovation leadership and bring unparalleled vision and value to Cognyte’s customers.

Among his previous leadership roles, Lempel led research and technology initiatives at Google Ads, Microsoft Azure Machine Learning, Outbrain and Yahoo, developing vast and varied expertise in Artificial Intelligence (AI), search engines, recommendation systems and ad tech. Lempel’s distinguished expertise in these fields combined with his military experience in an intelligence unit come together to drive AI innovation and bring added value for customers.

Lempel’s appointment as CTO reflects Cognyte’s commitment to continued technology foresight, future-proofing its product portfolio to deliver long-term innovative solutions that customers in law enforcement, national security, national intelligence and military intelligence agencies rely on to successfully safeguard their societies, assets and interests. Lempel’s leadership experience developing and deploying machine learning (ML) models and advanced algorithms is a natural complement to Cognyte’s platform architecture, robust R&D, and strong focus on AI, Large Language Models (LLMs) and more.

“As AI evolves, the CTO plays a pivotal role in anticipating technology trends that advance customers’ strategic missions. AI can deliver great value to our customers by expediting their investigations,” said Elad Sharon, Chief Executive Officer at Cognyte. “As CTO, Ronny will integrate cutting-edge research in line with our business objectives to drive innovation, maximize customer value, exceed market demands and ensure sustained company growth.”

“Cognyte has given me the unique opportunity to apply my research and development acumen and military intelligence experience to the cause of helping customers protect the safety of their societies,” commented Ronny Lempel. “Working collaboratively with Cognyte’s incredibly talented team, we will continue to innovate future-proof solutions that scale and adapt to tomorrow’s technology shifts.”

Lempel holds a Ph.D. in computer science from the Technion – Israel Institute of Technology, where he has taught advanced courses on search engine and big data technologies. He has published over 45 research papers and holds 23 U.S. patents.

About Cognyte Software Ltd.

Cognyte Software Ltd. is a global leader in investigative analytics software that empowers a variety of government and other organizations with Actionable Intelligence for a Safer World™. Our open interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making. Hundreds of customers rely on our solutions to accelerate and conduct investigations and derive insights, with which they identify, neutralize and tackle threats to national security and address different forms of criminal and terror activities. Learn more at www.cognyte.com.

Media Relations:

Michelle Allard McMahon

Rainier Communications on behalf of Cognyte Software

[email protected]

KEYWORDS: United States North America Israel Middle East New York

INDUSTRY KEYWORDS: Technology Homeland Security Law Enforcement/Emergency Services Military Public Policy/Government Professional Services Artificial Intelligence Defense Telecommunications Software Data Analytics Data Management Security Government Technology

MEDIA:

Photo
Photo
Cognyte appointed Dr. Ronny Lempel as Chief Technology Officer (CTO) to guide AI-focused research. In this role, Lempel will apply more than 25 years of proven, cross-discipline technology expertise to extend Cognyte’s innovation leadership and bring unparalleled vision and value to Cognyte’s customers.
Logo
Logo

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

  • In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death.
  • Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function.
  • Data support the potential of ZyVersa’s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities.

WESTON, Fla., March 18, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate <50%.

“These data contribute to a growing body of scientific evidence that obesity-related heart disease can be attenuated with inflammasome inhibition, providing support for ZyVersa’s Inflammasome ASC Inhibitor IC 100 as a potential therapeutic option for this obesity-related metabolic comorbidity,” said Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “Various cardiovascular diseases are associated with activation of multiple inflammasomes (NLRP1, NLRP3, NLRC4, and AIM2). IC 100, which targets the ASC component of inflammasomes, inhibits all four of these inflammasomes, which we believe will lead to better control of inflammation than targeting just the NLRP3 inflammasome. Likewise, IC 100 inhibits the function of ASC Specks released from inflamed, injured cells that spread inflammation to surrounding tissues leading to development and progression of comorbidities, such as heart disease.”

The article published in the peer-reviewed Journal of the American Heart Association was titled Impeding Nucleotide-Binding Oligomerization Domain-Like Receptor 3 Inflammasome Ameliorates Cardiac Remodeling and Dysfunction in Obesity-Associated Cardiomyopathy. The researchers report data from studies conducted in a diet-induced obesity cardiomyopathy mouse model.

Key Findings

NLRP3 Inflammasome Inhibition:

  • Reduced body weight and fasting blood glucose in obese mice after 24 weeks on a high fat diet.
  • Reduced cardiac inflammation.
  • Prevented myocardial hypertrophy (enlarged heart muscle), fibrosis, and cardiac dysfunction (both systolic and diastolic), restoring maximal oxygen consumption rate.
  • Attenuated cardiac lipid accumulation that promotes progression of obesity-induced heart failure.

The authors concluded, “Our study confirms that aberrant NLRP3 inflammasome activation in cardiomyocytes worsens obesity-associated cardiomyopathy and implicates inhibition of NLRP3 inflammasome as a potent therapeutic approach for obesity cardiomyopathy.”

About Inflammasome ASC Inhibitor IC 100

IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, and Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1β early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1β and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response. The lead indication for IC 100 is obesity with certain metabolic complications. To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux MediatorTM VAR 200. The lead indication for IC 100 is obesity and its associated metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.

Corporate, Media, and IR Contact:

Karen Cashmere
Chief Commercial Officer
[email protected]
786-251-9641



Worksport Believes Market Valuation Does Not Fully Reflect Business Fundamentals; Targets Cash Flow Positivity and Meaningful Growth in 2025

West Seneca, New York, March 18, 2025 (GLOBE NEWSWIRE) — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, today shares proactive business commentary and outlines key catalyst events projected for 2025.

Corporate Valuation and Growth Outlook

  • Stock Valuation: Worksport Ltd. holds more than 170 registered and pending patents and trademarks, maintains $6 million cash on hand (as of March 3, 2025), and carries minimal debt (Debt-to-Asset Ratio of 0.32 as of December 31, 2024). The Company’s advanced U.S. manufacturing facility is designed to accommodate annual revenue streams of $100 million to $300 million, and total factory assets exceed current market capitalization. Management expects to approach cash flow positivity this year and believes the market has yet to fully recognize Worksport’s fundamental value. Worksport projects that 2025 revenues will be higher than the Company’s present valuation.
  • Accelerating Revenue: The Company’s revenues rose from $1.5 million in 2023 to $8.5 million in 2024, surpassing $1 million per month by the close of 2024. Worksport is focused on further acceleration, targeting $1 million per week within the next 12 to 24 months. Early indicators include a 30% expansion in Worksport’s dealer network in the first two months of 2025.
  • Margin Improvements and Investor Visibility: In tandem with rapid revenue growth, Worksport continues to see improvements in gross margins. Management anticipates further margin gains in the latter half of 2025, when the Company is targeting cash flow positivity. Investors can expect forthcoming announcements regarding significant new contracts, strategic partnerships, and developments in e-commerce. The Company’s full fourth quarter results and Annual Report on Form 10-K will be released on March 27, 2025 (Q4 2024 Earnings Call, sign up [here]).

COR & SOLIS Releases

  • SOLIS Solar Tonneau Cover Launch: Worksport remains on schedule to introduce its “SOLIS” Solar Tonneau Cover in 2025. Designed for both electric and traditional pickup trucks—the highest-selling vehicle segment—the SOLIS targets a tonneau cover market currently valued at $4 billion and projected to continue its healthy growth. SOLIS is in its final commercialization stages and currently in production at Worksport’s NY Factory.
  • COR Portable Energy System: The Company will also launch “COR”, a modular, portable energy system engineered for standalone use or seamless integration with SOLIS. COR delivers comprehensive off-grid power solutions suitable for diverse applications and lifestyles, capitalizing on a rapidly expanding portable energy market. Set to be produced in partnership with a reputable manufacturer, COR is slated for certification in Q2 2025.
  • Strong Revenue Impact: Management expects SOLIS and COR to contribute substantially to Worksport’s revenue as early as the third and fourth quarters of 2025. These new offerings, in combination with the Company’s existing tonneau cover business, are projected to support continued revenue gains and profitability into 2026 and beyond.

AetherLux– Heat Pump Breakthrough

  • Worksport’s subsidiary, Terravis Energy, has unveiled AetherLux, a revolutionary HVAC technology. The AetherLux system is the world’s first heat pump that eliminates defrost cycles, even in extreme temperatures—solving the industry’s biggest limitation and significantly improving efficiency. Following its global debut, AetherLux’s ZeroFrost technology has attracted strong interest from leading global corporations, recognizing its disruptive potential. Active discussions are underway with major industry players to explore its future applications. Worksport views this innovation as a valuable intellectual property asset and is committed to leveraging it to drive long-term shareholder value.

Closing Statement To Shareholders:

Worksport’s leadership believes the Company is uniquely positioned for continued significant growth, driven by the upcoming market launch of the SOLIS and COR product lines, ongoing expansion of its dealer network, and a commitment to operational excellence. Supported by a broad patent portfolio, accelerating revenue, improving margins, and a strong financial footing, Worksport’s management is confident that the current market valuation does not fully reflect the Company’s intrinsic value. Worksport remains focused on delivering meaningful long-term returns and looks forward to reporting further progress and milestones over the course of a transformative 2025.

Learn more about Worksport, here:

https://investors.worksport.com

.

Stay tuned for more information and join our mailing list to stay up to date with the latest. Join Worksport’s Newsletter

About Worksport

Worksport Ltd. (Nasdaq: WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport’s hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy’s website is terravisenergy.com.

For more information, please visit investors.worksport.com.

Connect with Worksport

Please follow the Company’s social media accounts on X (previously Twitter)Facebook, LinkedInYouTube, and Instagram (collectively, the “Accounts”), the links of which are links to external third-party websites, as well as sign up for the Company’s newsletters at investors.worksport.com. The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company.

Product social media Investor social media
Instagram X (formerly Twitter)
Facebook

YouTube
LinkedIn

Link to Newsletter
   

Investors and others should note that the Company announces material financial information to our investors using our investor relations website, press releases, Securities and Exchange Commission (“SEC”) filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media.

The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

For additional information, please contact:

Investor Relations, Worksport Ltd. T: 1 (888) 554-8789 -128 W: investors.worksport.com W: www.worksport.com E: [email protected]

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “scheduled,” “expect,” “future,” “intend,” “plan,” “project,” “envisioned,” “should,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; and (iv) competition from other producers of similar products. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

WKSP Investor Relations

Worksport Ltd.
Phone: 888-554-8789 x 128
Email: [email protected]
Website: investors.worksport.com



Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) — Wellgistics Health, Inc. (NASDAQ: WGRX) (“Wellgistics Health”), a provider of pharmacy solutions and healthcare technology, has successfully completed a third-party audit and achieved SOC 2 Type 1 compliance. This milestone validates that Wellgistics Health meets the industry’s highest standards for security, availability, processing integrity, confidentiality, and privacy, reinforcing its commitment to data protection and regulatory compliance.

SOC 2 Type 1 certification, developed by the American Institute of Certified Public Accountants (AICPA), confirms that Wellgistics Health has implemented strong security controls and operational safeguards to protect sensitive healthcare data. This compliance ensures that Wellgistics Health’s systems, policies, and procedures are designed to manage and secure customer information with the highest level of integrity.

“Achieving SOC 2 Type 1 compliance marks an important step in ensuring that our systems and processes meet the highest security and reliability standards,” said Srini Kalla, CIO at Wellgistics Health. “This certification demonstrates our commitment to protecting customer data and maintaining a strong foundation for future growth.”

The audit was conducted by Sensiba LLP, a nationally recognized CPA and advisory firm specializing in information security and compliance. As a Public Company Accounting Oversight Board (PCAOB)-registered firm, Sensiba LLP assessed Wellgistics Health’s security controls, risk management policies, and adherence to industry best practices. Their evaluation confirmed that Wellgistics Health’s IT infrastructure and operational processes align with SOC 2 Trust Service Criteria, ensuring a robust security framework for its healthcare partners.

With SOC 2 Type 1 compliance, Wellgistics Health reinforces its ability to provide secure, scalable, and compliant pharmacy solutions for healthcare organizations. This achievement strengthens Wellgistics Health’s position as a trusted partner for pharmacies, providers, and health systems seeking reliable and compliant technology solutions.

About Wellgistics Health

Wellgistics Health, Inc. is a holding company for existing and future planned operating companies centered around healthcare technology and pharmaceutical services. It seeks to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. Wellgistics Health is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, Wellgistics Health intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from “specialty-lite” to general maintenance conditions. For more information, please visit Wellgistics Health’s website at www.wellgisticshealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health’s statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health ‘s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, which are available for review at www.sec.gov. Wellgistics Health undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:


[email protected]



IHS Holding Limited Files its Annual Report on Form 20-F

IHS Holding Limited Files its Annual Report on Form 20-F

LONDON & NEW YORK–(BUSINESS WIRE)–
IHS Holding Limited (NYSE: IHS) (“IHS Towers”), today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission on March 18, 2025. The annual report on Form 20-F can be accessed on the investor relations section of the Company website at http://ihstowers.com/investors or on the SEC’s website at www.sec.gov.

IHS Towers will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed in writing by email to [email protected].

About IHS Towers: IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count and is solely focused on the emerging markets. The Company has over 39,000 towers across its eight markets, including Brazil, Cameroon, Colombia, Côte d’Ivoire, Nigeria, Rwanda, South Africa and Zambia. For more information, please email: [email protected] or visit: www.ihstowers.com

[email protected]

www.ihstowers.com

KEYWORDS: Europe United States United Kingdom North America New York

INDUSTRY KEYWORDS: Networks Mobile/Wireless Technology Carriers and Services Telecommunications

MEDIA:

Insulet Announces Proposed Financing Transactions

Insulet Announces Proposed Financing Transactions

ACTON, Mass.–(BUSINESS WIRE)–
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement.

The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company’s existing capped call transactions relating to the Company’s existing 0.375% Convertible Senior Notes due 2026 (the “Convertible Senior Notes”), (i) to finance the redemption, repurchase, repayment, satisfaction, and discharge or other payment of all or a portion of the Convertible Senior Notes, which may include one or more repurchases pursuant to privately negotiated transactions, and the payment of accrued and unpaid interest thereon, (ii) to pay any fees, costs, and expenses relating to the offering of the Notes and Credit Agreement transactions described below and/or (iii) for general corporate purposes. The Notes offering is subject to market and other conditions, and may not occur as described or at all.

The Company also today announced its intention to amend its existing Credit Agreement to, among other things, extend the maturity of the Company’s revolving credit facility from 2028 to 2030 and increase the amount of revolving credit commitments by up to $200 million (resulting in aggregate commitments of up to $500 million). The terms of the commitments and loans under the amended revolving credit facility are expected to be substantially similar to those relating to the commitments and loans under the existing revolving credit facility, except with respect to the aggregate amount of commitments thereunder, the maturity date thereof and certain other terms. The Credit Agreement amendments are subject to market and other conditions, and may not occur as described or at all. The consummation of the Notes offering is not conditioned on the consummation of the Credit Agreement amendments and the consummation of the Credit Agreement amendments are not conditioned on the consummation of the Notes offering.

The Notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and only to non-U.S. persons outside the United States pursuant to Regulation S.

The Notes have not been registered under the Securities Act or any applicable state securities laws. As a result, the Notes may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws.

This press release does not and will not constitute an offer to sell or a solicitation of an offer to buy any securities nor will there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful under the securities laws of such state. Any offer of the Notes will be made only by means of a private offering memorandum. This press release does not and will not constitute an offer to repurchase the Convertible Senior Notes, nor do the statements herein constitute a notice of redemption under the indenture governing the Convertible Senior Notes.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Forward-Looking Statements:

This press release contains forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs or strategies regarding the future, including the offering of the Notes, the use of proceeds from the offering of the Notes and the Credit Agreement amendments. These forward-looking statements are based on Insulet’s current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Insulet’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in Insulet’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled “Risk Factors”, and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

Investor Relations:

June Lazaroff

Senior Director, Investor Relations

(978) 600-7718

[email protected]

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Wearables/Mobile Technology Apps/Applications Technology Mobile/Wireless Medical Devices Diabetes Health Technology Managed Care Health

MEDIA:

Logo
Logo

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform

Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today that it initiated its Phase I/IIa clinical trial investigating the safety, tolerability and full pharmacokinetic profile of its innovative treatment, CMND-100, in Alcohol Use Disorder (AUD) patients. This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company’s mission to provide innovative solutions for addictions, weight loss and mental health disorders.

The first site to be initiated is IMCA in Israel and will be led by Prof. Mark Weiser, head of the Psychiatric Division at the Sheba Medical Center, whose specializations include cognitive impairment in persons with psychiatric disorders, such as substance abuse, depression and personality disorders.

“Transitioning to a clinical stage pharmaceutical company is a major milestone for our Company, enabling us to evaluate whether the promising results from our animal studies will translate to human clinical trial participants with AUD,” said Adi Zuloff-Shani, Ph.D., Clearmind’ s Chief Executive Officer. “Previously announced preclinical data on alcohol curb supports the potential ofCMND-100 as a novel and effective treatment approach for alcoholism, addressing a significant unmet medical need.”

The Phase I/IIa trial is designed to assess the safety, tolerability, and pharmacokinetics of CMND-100 in individuals diagnosed with AUD. The study will also include preliminary efficacy evaluations, examining the drug’s potential to reduce alcohol cravings and consumption.

In addition to the IMCA Center in Israel, the trial will be conducted at two prestigious U.S. research institutions, Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of Medicine.

CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel approach by modulating reward mechanisms associated with addictive behavior.

Addressing the Global Alcohol Use Disorder Crisis

Alcohol Use Disorder remains a major global health challenge, affecting millions of individuals worldwide. The disorder is linked to severe health complications, including liver disease, cardiovascular issues, and mental health disorders. Current treatment options remain limited and often ineffective, highlighting the urgent need for innovative therapeutic solutions.

AUD continues to be a significant global health concern, affecting millions worldwide. According to the World Health Organization (WHO), approximately 400 million people aged 15 years and older live with alcohol use disorders, with 209 million experiencing alcohol dependence. ​The impact of alcohol consumption is profound, contributing to 2.6 million deaths annually, accounting for 4.7% of all global deaths. Notably, 13% of these deaths occur among individuals aged 20 to 39, highlighting the vulnerability of younger populations. ​In the United States, the prevalence of AUD among young adults is particularly alarming. Data from the 2023 National Survey on Drug Use and Health (NSDUH) indicates that 15.1% of adults aged 18 to 25 met the criteria for past-year AUD. ​

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com or contact:

Investor Relations
[email protected]

Telephone: (604) 260-1566
US: [email protected]

General Inquiries


[email protected]


www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses transitioning to a clinical stage pharmaceutical company and the potential for CMND-100 to provide a novel, effective approach to alcoholism treatment, addressing a major unmet medical need.  Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.



IHS Holding Limited Reports Fourth Quarter and Full Year 2024 Financial Results

IHS Holding Limited Reports Fourth Quarter and Full Year 2024 Financial Results

FULL YEAR 2024 FINANCIAL RESULTS AHEAD OF GUIDANCE

SIGNIFICANT PROGRESS MADE DELIVERING STRATEGIC REVIEW

LONDON–(BUSINESS WIRE)–
IHS Holding Limited (NYSE: IHS) (“IHS Towers” or the “Company”), one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, today reported financial results for the fourth quarter and full year ended December 31, 2024.

CONSOLIDATED HIGHLIGHTS – FOURTH QUARTER AND FULL YEAR 2024

The table below sets forth the select financial results for the three months and twelve months ended December 31, 2024 and December 31, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended December 31,

 

Full year ended December 31,

 

 

2024

 

2023

 

 

Change

 

2024

 

2023

 

Change

 

 

$’million

 

$’million

 

%

 

$’million

 

$’million

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

437.8

 

509.8

 

 

(14.1

)

 

1,711.2

 

 

2,125.5

 

 

(19.5

)

Adjusted EBITDA(1)

 

246.4

 

274.2

 

 

(10.1

)

 

928.4

 

 

1,132.5

 

 

(18.0

)

Income/(loss) for the period

 

243.1

 

(456.8

)

 

153.2

 

 

(1,644.2

)

 

(1,988.2

)

 

17.3

 

Cash from operations

 

348.8

 

162.1

 

 

115.3

 

 

775.9

 

 

902.9

 

 

(14.1

)

ALFCF(1)

 

107.1

 

118.2

 

 

(9.3

)

 

304.2

 

 

432.8

 

 

(29.7

)

 

(1) Adjusted EBITDA and ALFCF are non-IFRS financial measures. See “Use of Non-IFRS financial measures” for additional information, definitions and a reconciliation to the most comparable IFRS measures.

FOURTH QUARTER 2024

Financial Highlights

  • Revenue of $437.8 million increased 4.2% compared to the third quarter of 2024 with continued growth in revenue from Colocation, Lease Amendments and New Sites, more than offsetting the slight depreciation of the Nigerian Naira (“NGN”) versus the U.S. dollar (“USD”)
  • Revenue decreased 14.1% year-on-year and increased 39.3% on an organic basis. Organic growth was driven by 9.2% Constant Currency(1) growth with the remainder a result of foreign exchange (“FX”) resets and power indexation, which helped to mitigate the non-core decline of 53.1% primarily driven by the 50.0% NGN devaluation, the majority of which occurred during the first quarter of 2024
  • Adjusted EBITDA of $246.4 million (down 10.1% year-on-year) reached an Adjusted EBITDA Margin of 56.3%, an increase of 250 basis points year-on-year, driven by continued financial discipline
  • Income for the period was $243.1 million of which $169.9 million related to unrealized FX gains
  • Adjusted Levered Free Cash Flow (“ALFCF”) of $107.1 million with cash from operations of $348.8 million
  • Capital expenditure (“Total Capex”) of $82.6 million, down 36.8% year-on-year, reflecting actions being taken to improve cash generation
  • Full year 2024 financial results ahead of guidance across all metrics
  • Consolidated net leverage ratio(2) of 3.7x, down 0.2x from the third quarter of 2024, within the target of 3.0x-4.0x

Strategic and Operational Highlights

  • Completed the disposal of IHS Towers’ 70% interest in IHS Kuwait Limited at an Enterprise Value(3) of $230 million as part of the ongoing strategic review targeted at shareholder value-creation options
  • Extended maturity profile and shifted more debt into local currency through a $439 million equivalent dual-tranche term loan with proceeds used to repay existing $430 million term loan due to mature in October 2025
  • Raised $1.2 billion from the issuance of dual tranche senior notes, with proceeds used to refinance in part the Group’s shorter maturity notes, reducing shorter term maturities due in 2026 and 2027
  • Reduced volatility of the NGN compared to earlier in the year, with 8.0% appreciation versus the USD during the quarter. Continued USD availability, with $153 million upstreamed from Nigeria alone in the quarter
  • Continued organic growth in Towers (39,229) and Tenants (59,343) reaching a Colocation Rate of 1.51x at the end of the fourth quarter. Lease Amendments increased to 39,671 during the period

(1) “Constant Currency” combines the impact from CPI escalation, New Sites, new Colocation, new Lease Amendments, fiber and other revenues, as captured in organic revenue. Refer to “Item 5. Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for the definition of organic revenue and additional information.

(2) Refer to note 4(e) in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for further information on the calculation of this figure.

(3) Enterprise Value” is defined as anticipated cash consideration to be received (as of December 2, 2024, the date of transaction announcement) plus borrowings less cash in the business and stated for a 100% shareholding. Refer to note 31.2 in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for further information on the disposal of the Kuwait business.

FULL YEAR 2024

Financial Highlights

  • Revenue of $1,711.2 million decreased by 19.5% (and increased by 48.1% on an organic basis) year-on-year, primarily driven by the non-core impact of the 57% devaluation of the Nigerian Naira
  • Organic revenue growth was driven by 6.5% Constant Currency growth, with continued growth in revenue from Colocation, Lease Amendments and New Sites, with the remainder a result of FX resets and power indexation
  • Adjusted EBITDA of $928.4 million reached an Adjusted EBITDA Margin of 54.3%, an increase of 100 basis points year-on-year, reflecting continued cost control
  • Loss for the period was $1,644.2 million of which $1,610.7 million related to unrealized FX losses
  • ALFCF was $304.2 million with cash from operations of $775.9 million
  • Total Capex of $255.9 million was down 56.3% year-on-year, reflecting a narrowed focus on capital allocation

Strategic and Operational Highlights

  • Initiated strategic review in March 2024 targeted at shareholder value-creation options with significant progress made:
  • Material commercial progress including the renewal and extension of all MTN tower MLAs and extension of Airtel Nigeria MLA, covering approximately 72% of group revenue
  • Reduced risk in operating model by materially reducing exposure to power prices, with expectation to result in reduced earnings volatility. Included introducing power indexation to use fees with MTN in Nigeria, and unbundling the power Managed Services contract with MTN in South Africa
  • Significant advances made on balance sheet strategy through extending maturity profile and shifting more debt into local currency
  • Disposal of IHS Towers’ 70% interest in IHS Kuwait Limited at an Enterprise Value of $230 million, highlighting the value within the Group’s wider portfolio of assets
  • Amended articles of association to better align governance framework with that of mature US listed companies
  • Continued USD availability, allowing us to source and upstream $271 million from Nigeria alone during the year

Sam Darwish, IHS Towers Chairman and Chief Executive Officer, stated, “We’re reporting a strong performance in the fourth quarter, with our key metrics revenue, Adjusted EBITDA and ALFCF all ahead of our guidance, while Total Capex was below expectations, and we saw a drop in our consolidated net leverage ratio. We believe our positive momentum reflects both the continued strong secular trends we are seeing across our business, a more stable macroeconomic environment, as well as the significant commercial and financial progress we have made during 2024 as part of our ongoing strategic review. We have de-risked our business through extending commercial contracts with Key Customers into the next decade, reduced our exposure to power prices, extended our debt maturities and completed some of our disposals target.

Looking to 2025 and beyond, we remain excited by the strong structural growth opportunities across our footprint. We believe we are well placed to leverage our market leading positions and support growing demand for our critical communications infrastructure, with growth underpinned by continued 5G deployment across our markets and an improving backdrop within our largest market Nigeria after recent carrier tariff rate increases. As we enter 2025, we remain focused on further enhancing our profitability and cash flow generation, as can be seen in our FY25 guidance, and are committed to further strengthening our balance sheet, supported by potential further select asset disposals, allowing us to deliver increasing returns for all our stakeholders.”

Full Year 2025 Outlook Guidance

The following full year 2025 guidance is based on a number of assumptions that management believes to be reasonable and reflects the Company’s expectations as of March 18, 2025. Actual results may differ materially from these estimates as a result of various factors, and the Company refers you to the cautionary language regarding “forward-looking” statements included in this press release when considering this information.

The Company’s outlook is based on the following:

  • Organic revenue Y/Y growth of approximately 12% (at the mid-point)
  • Average foreign currency exchange rates to 1.00 U.S. dollar for January 1, 2025, through December 31, 2025, for key currencies: (a) 1,640 Nigerian Naira; (b) 5.90 Brazilian Real (c) 0.96 Euros (d) 18.50 South African Rand
  • No contribution from Kuwait and Peru operations sold during 2024
  • Revenue withholding tax in Nigeria reduced from 10% to 2% effective January 1, 2025
  • Approximately 500 Build-to-suit sites, of which approximately 400 sites in Brazil
  • Consolidated net leverage ratio target of 3.0x-4.0x

 

 

 

Metric

 

Current Range

Revenue

 

$1,680M-1,710M

Adjusted EBITDA (1)

 

$960M-980M

Adjusted Levered Free Cash Flow (1)

 

$350M-370M

Total Capex

 

$260M-290M

 

(1) Adjusted EBITDA and ALFCF are non-IFRS financial measures. See “Use of Non-IFRS financial measures” for additional information and a reconciliation to the most comparable IFRS measures. We are unable to provide a reconciliation of Adjusted EBITDA and ALFCF to (loss)/income and cash from operations, respectively, presented above without an unreasonable effort, due to the uncertainty regarding, and the potential variability, of these costs and expenses that may be incurred in the future, including, in the case of Adjusted EBITDA, share-based payment expense, finance costs, insurance claims and gain on disposal of subsidiary, and in the case of ALFCF, cash from operations, net movement in working capital and maintenance capital expenditures, each of which adjustments may have a significant impact on these non-IFRS measures.

RESULTS OF OPERATIONS FOR THE FOURTH QUARTER AND FULL YEAR 2024

Impact of Nigerian Naira devaluation

Following the steps taken by the Central Bank of Nigeria, the Naira devalued between the period immediately prior to the announcement and the month end rate as of June 30, 2023. The Naira continued to devalue in the second half of 2023 and in January 2024, there was a further significant devaluation. During the second and third quarters of 2024, the Naira continued to devalue but at a significantly slower rate as compared to the first quarter of 2024. During the fourth quarter of 2024, this trend reversed resulting in an appreciation of the Naira closing rate at the end of the fourth quarter compared to the end of third quarter of 2024.

In November 2024, the Central Bank of Nigeria directed authorized dealers to use a new trading platform – Bloomberg BMatch as the Electronic Foreign Exchange Matching System (“EFEMS”) for foreign exchange related activities. It is expected the platform would enhance the integrity and operational efficiency of the foreign exchange market by providing greater price discovery.

Set out below are the closing and average rates for the Naira currency relevant to these financial statements:

 

 

 

 

 

 

Closing Rate

Closing Rate Movement (1)

3- Month Average Rate

Average Rate Movement (1)

 

₦:$

$:₦

₦:$

$:₦

 

 

 

 

 

June 14, 2023

472.3

June 30, 2023

752.7

(37.3)%

508.0

September 30, 2023

775.6

(2.9)%

767.7

(33.8)%

December 31, 2023

911.7

(14.9)%

815.0

(5.8)%

March 31, 2024

1,393.5

(34.6)%

1,315.9

(38.1)%

June 30, 2024

1,514.3

(8.0)%

1,391.8

(5.4)%

September 30, 2024

1,669.1

(9.3)%

1,601.0

(13.1)%

December 31, 2024

1,546.0

8.0%

1,628.5

(1.7)%

 
(1) Movements presented for each period are between that period’s rate and the preceding period rate and are calculated as percentage of the period’s rate.

Due to the Naira devaluation, Revenue and segment Adjusted EBITDA in the fourth quarter of 2024 were negatively impacted by $259.0 million and $155.2 million, respectively, compared to the same period in 2023. In the fourth quarter of 2024, the foreign exchange resets in some of our contracts partially offset these impacts. However, the appreciation of the Naira in the fourth quarter of 2024 resulted in unrealized foreign exchange gains of $166.9 million on USD denominated intercompany loans advanced to our Nigerian operations (partially offsetting the unrealized losses in the previous quarters of 2024). The unrealized gains and losses are recorded in finance costs, however Group net assets are not impacted since equal and opposite gains and losses are recorded in equity on the retranslation of the Nigerian operations’ assets and liabilities (which include these loans). The assets included property, plant and equipment and the devaluation of the Naira from December 31, 2023 to December 31, 2024 resulted in a $261.5 million reduction in their carrying value.

Results for the three months ended December 31, 2024 versus 2023

Revenue

Revenue for the three months ended December 31, 2024 of $437.8 million declined 14.1% year-on-year, driven primarily by the devaluation of the Naira versus the U.S. dollar. Organic revenue(1) increased by $200.5 million (increased 39.3%) year-on-year during the fourth quarter driven primarily by foreign exchange resets, power indexation, escalations, and continued growth in revenues from Tenants, Lease Amendments and New Sites. This growth was partially offset by the initial impact of the new financial terms in the renewed and extended contracts with MTN Nigeria, signed during the third quarter of 2024. Aggregate inorganic revenue declined $1.7 million, which primarily related to the disposal of operations in Kuwait in December 2024. The increase in organic revenue was more than offset by the non-core impact of adverse movements in foreign exchange rates used to translate the results of foreign operations of $270.7 million, or 53.1%, of which $259.0 million was due to the devaluation of the Naira.

In December, 2024, the Company completed the disposal of its 70% interest in IHS Kuwait Limited, resulting in 12 fewer trading days for this operation in both the three month and full year periods ended December 31, 2024 when compared to the equivalent periods ended December 31, 2023. The revenue from the equivalent 12 day comparative period after December 19, 2023 is captured within inorganic revenue. Given the disposal date of December 19, 2024, as of December 31, 2024 the entire Tower portfolio, Tenants and Lease Amendments in Kuwait had been deconsolidated. Refer to note 31.2 in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for further information on the disposal of the Kuwait business.

Refer to the revenue component of the segment results section of this discussion and analysis for further details.

For the fourth quarter, the net decrease in Towers was 846 year-on-year (or a net increase of 896 year-on-year when excluding the impact of the Kuwait and Peru disposals), resulting in total Towers of 39,229 at the end of the period. The decrease primarily resulted from the divestiture of 1,678 Towers from Kuwait and 64 Towers from Peru. The addition of 929 New Sites, was partially offset by 250 Churned and 15 decommissioned. Tenants declined 384 year-on-year (including the net divestiture of 1,700 and 66 from Kuwait and Peru, respectively, and a reduction of 529 Tenants, in the third quarter of 2024, occupied by our smallest Key Customer on which we were not recognizing revenue), resulting in total Tenants of 59,343 and a Colocation Rate of 1.51x at the end of the fourth quarter. Excluding the impact of the Kuwait and Peru disposals, we added 1,382 net new tenants year-on-year. Year-on-year, we added 3,068 Lease Amendments, driven primarily by 5G and fiber upgrades, partially offset by the net divestiture of 272 from Kuwait, resulting in total Lease Amendments of 39,671 at the end of the fourth quarter.

(1) Refer to “Item 5. Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for the definition of organic revenue and additional information.

Adjusted EBITDA

Adjusted EBITDA for the fourth quarter was $246.4 million, resulting in an Adjusted EBITDA margin of 56.3%. Adjusted EBITDA decreased 10.1% year-on-year in the fourth quarter reflecting the decrease in revenue described above, partially offset by a decrease in cost of sales included within Adjusted EBITDA. The reduction in cost of sales was primarily driven by a decrease in regulatory fees of $10.6 million, mostly relating to a non-recurring review of the current and historical license obligations in the SSA segment, and a decrease in power generation costs ($7.9 million), security services costs ($3.9 million), tower repairs and maintenance costs ($2.6 million), and staff costs ($1.9 million). The $4.0 million increase in other cost of sales was primarily driven by a non-recurring write-down of inventory in the period. The $21.5 million reduction in administrative costs included within Adjusted EBITDA was largely driven by a devaluation of the Naira against the U.S. dollar, supported by cost saving initiatives implemented during the period.

Income for the period

Income for the period in the fourth quarter of 2024 was $243.1 million, compared to a loss of $456.8 million for the fourth quarter of 2023. This equates to an increase of income of $699.9 million year-on-year, driven primarily by a $636.7 million decrease in net finance costs. The decrease in net finance costs was mainly due to the impact of the movement in the Naira rate in the respective quarters on USD denominated intercompany loans advanced to our Nigerian operations. In the fourth quarter of 2023, the Naira devaluation led to a foreign exchange loss, whereas in the current quarter the Naira appreciated giving rise to a gain. Further, the current quarter included a $83.9 million gain from the disposal of our Kuwait subsidiary. This was partially offset by the decrease in revenue as described above.

Cash from operations

Cash from operations for the fourth quarter of 2024 was $348.8 million, compared to $162.1 million for the fourth quarter of 2023. The increase reflects an improvement in working capital movements of $196.1 million (inclusive of a withholding tax receivable decrease of $20.8 million), partially offset by a decrease in operating income before working capital changes of $9.3 million.

ALFCF

ALFCF for the fourth quarter of 2024 was $107.1 million, compared to $118.2 million for the fourth quarter of 2023. The decrease in ALFCF was primarily due to the decrease in cash from operations before working capital movements of $9.3 million described above, an increase in net interest paid of $9.8 million, partially offset by a reduction in withholding tax of $6.7 million and maintenance and corporate capex of $2.6 million.

SEGMENT RESULTS

Revenue and Adjusted EBITDA by segment

Set out below are Revenue and Adjusted EBITDA for each of our reportable segments for the three months ended December 31, 2024 and 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

Adjusted EBITDA

 

 

 

Three months ended December 31,

 

Three months ended December 31,

 

 

 

2024

 

2023

 

Change

 

2024

 

2023

 

Change

 

 

 

$’000

 

$’000

 

%

 

$’000

 

$’000

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nigeria

 

258,870

 

320,662

 

(19.3

)

 

154,871

 

 

199,841

 

 

(22.5

)

 

SSA

 

124,173

 

124,016

 

0.1

 

 

80,800

 

 

62,373

 

 

29.6

 

 

Latam

 

44,645

 

54,331

 

(17.8

)

 

37,113

 

 

41,089

 

 

(9.7

)

 

MENA

 

10,134

 

10,775

 

(5.9

)

 

7,308

 

 

7,916

 

 

(7.7

)

 

Unallocated corporate expenses(1)

 

 

 

 

 

(33,720

)

 

(37,037

)

 

9.0

 

 

Total

 

437,822

 

509,784

 

(14.1

)

 

246,372

 

 

274,182

 

 

(10.1

)

 

 

(1) Unallocated corporate expenses primarily consist of costs associated with centralized Group functions including Group executive, legal, finance, tax and treasury services.

Nigeria

Fourth quarter revenue decreased 19.3% year-on-year to $258.9 million, primarily driven by devaluation of the NGN versus the U.S. dollar. When compared to the third quarter of 2024, revenue increased 6.8%. Organic revenue increased by $197.2 million (61.5%) year-on-year driven primarily by foreign exchange resets and diesel prices, as well as continued growth in revenue from Colocation and Lease Amendments, partially offset by a reduction in revenues related to the new financial terms in the renewed contracts with MTN Nigeria, signed during the third quarter of 2024. The decrease in reported revenue was primarily driven by the impact of negative movements in foreign exchange rates used to translate the results of foreign operations, with an average Naira rate of ₦1,629 to $1.00 in the fourth quarter of 2024 compared to the average rate of ₦815 to $1.00 in the fourth quarter of 2023. This led to a non-core decline of $259.0 million, or 80.8% year-on-year.

Tenants decreased by 269 year-on-year, with growth of 528 from Colocation and 96 from New Sites, more than offset by 893 Churned (which includes, for the third quarter of 2024, 529 Tenants occupied by our smallest Key Customer on which we were not recognizing revenue), while Lease Amendments increased by 1,035 primarily due to 3G and fiber upgrades.

Segment Adjusted EBITDA for the fourth quarter declined 22.5% year-on-year to $154.9 million, for a margin of 59.8%. When compared to the third quarter of 2024, segment Adjusted EBITDA declined 2.5%. The year-on-year decline in segment Adjusted EBITDA for the fourth quarter primarily reflects the decrease in revenue described above, partially offset by a reduction in cost of sales and administrative expenses included within segment Adjusted EBITDA, primarily due to the devaluation of the Naira which is used to translate the results of our Nigeria operations. During the fourth quarter there was a decrease in costs of sales, including a reduction in the cost of diesel ($3.4 million), tower repairs and maintenance costs ($1.6 million), security services costs ($1.2 million) and staff costs ($1.7 million), even though the underlying Naira-based costs increased during the period. The $4.9 million increase in other cost of sales was primarily driven by a non-recurring write-down of inventory in the period.

SSA

Fourth quarter revenue was broadly flat year-on-year at $124.2 million, primarily driven by movements in organic revenue, which increased by $3.9 million, or 3.1%, due to factors including new Tenants, Colocations, Lease Amendments in addition to CPI escalators, offset by $4.5 million lower power pass-through revenues being recognized after the changes in our agreements with MTN South Africa relating to the provision of power Managed Services. These changes to power pass-through revenue have no impact on segment Adjusted EBITDA. Other factors impacting organic revenue included growth in Tenants, New Sites and Lease Amendments, together with escalations and foreign exchange resets. The growth in organic revenue in the third quarter was offset by the non-core impact of negative movements in foreign exchange rates of $3.7 million, or 3.0%.

Tenants increased by 835 year-on-year, including 814 from Colocation and 127 from New Sites, partially offset by 106 from Churn, while Lease Amendments increased by 1,687.

Segment Adjusted EBITDA for the fourth quarter grew 29.6% year-on-year to $80.8 million, for a margin of 65.1%. The year-on-year increase in segment Adjusted EBITDA for the fourth quarter primarily reflects a decrease in cost of sales included within Adjusted EBITDA of $19.3 million, driven by reduced regulatory fees ($11.0 million) primarily relating to a non-recurring review of the current and historical license obligations, and reduced tower repairs and maintenance costs ($1.5 million), security services costs ($3.0 million) and power generation costs ($4.1 million) driven by the changes in our agreements with MTN South Africa described above.

Latam

Fourth quarter revenue decreased 17.8% year-on-year to $44.6 million and was primarily driven by the non-core impact of adverse movements in foreign exchange rates of $8.0 million, or 14.7%. Organic revenue declined 2.7% in the quarter, or $1.5 million, driven by a reduction in revenues from our customer Oi S.A. (“Oi Brazil”) of $3.8 million as a result of their judicial recovery proceedings, partially offset by continued growth in Tenants, Lease Amendments and New Sites.

Tenants increased by 746 year-on-year, including 697 from New Sites and 309 from Colocation, partially offset by 194 Churned and net divestiture of 66, due to the disposal of our Peru operations, while Lease Amendments increased by 346.

Fourth quarter segment Adjusted EBITDA declined 9.7% to $37.1 million, for a margin of 83.1%, and primarily reflects the decrease in revenue described above, partially offset by a reduction in staff cost of sales ($0.4 million) and site rental costs ($1.2 million).

MENA

On December 19, 2024, the Company completed the disposal of its 70% interest in IHS Kuwait Limited, resulting in 12 fewer trading days for this operation, equating to a reduction to revenue of $1.5 million, in both the three month and full year periods ended December 31, 2024 when compared to the equivalent periods ended December 31, 2023. The revenue from the equivalent 12 day comparative period after December 19, 2023 is captured within inorganic revenue. Given the disposal date of December 19, 2024, as of December 31, 2024 the entire Tower portfolio, Tenants and Lease Amendments had been deconsolidated. Refer to note 31.2 in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for further information on the disposal of the Kuwait business.

Fourth quarter revenue decreased 5.9% year-on-year to $10.1 million which included the impact of 12 fewer days of IHS Kuwait results following the sale of this operation to Zain Kuwait on December 19, 2024 more than offsetting growth primarily by New Sites, Lease Amendments and escalations. Revenues declined inorganically in the period by $1.5 million, or 13.9%, reflecting the disposal of this operation to Zain Kuwait described above.

Prior to the disposal in December 2024, Tenants increased by 4 for the year, including 9 from New Sites, partially offset by 5 Churned sites, while Lease Amendments increased by 272, resulting in 1,678 Towers, 1,700 Tenants and 272 Lease Amendments. Following completion of the Kuwait Dispoal and as of December 31, 2024 these Tower, Tenants and Lease Amendments had been deconsolidated.

Segment Adjusted EBITDA was $7.3 million for the fourth quarter, a decrease of 7.7% year-on-year. The decrease in segment Adjusted EBITDA primarily reflects the decrease in revenue described above, with year-on-year growth impacted by 12 fewer days of IHS Kuwait results following the sale of this operation to Zain Kuwait on December 19, 2024.

CAPITAL EXPENDITURE

Set out below is the capital expenditure for the three months ended December 31, 2024 and 2023 for each of our reporting segments:

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended December 31,

 

 

 

 

 

 

 

2024

 

2023

 

Change

 

Change

 

 

 

$’000

 

$’000

 

$’000

 

%

 

 

 

 

 

 

 

 

 

 

 

Nigeria

 

33,719

 

66,703

 

(32,984

)

 

(49.4

)

 

SSA

 

17,070

 

11,348

 

5,722

 

 

50.4

 

 

Latam

 

30,951

 

50,809

 

(19,858

)

 

(39.1

)

 

MENA

 

179

 

1,276

 

(1,097

)

 

(86.0

)

 

Other

 

682

 

492

 

190

 

 

38.6

 

 

Total capital expenditure

 

82,601

 

130,628

 

(48,027

)

 

(36.8

)

 

During the fourth quarter of 2024, capital expenditure was $82.6 million, compared to $130.6 million for the fourth quarter of 2023. The decrease is primarily driven by lower capital expenditure across our Nigeria and Latam segments reflecting the actions we are taking to improve cash generation and to narrow our focus on capital allocation.

Nigeria

The 49.4% year-on-year decrease for the fourth quarter was primarily driven by decreases of $17.1 million related to Project Green given the investment planned for this project is now largely complete, $5.1 million related to augmentation, $3.2 million related to maintenance and $8.0 million related to other capital expenditure.

SSA

The 50.4% year-on-year increase for the fourth quarter was primarily driven by increases in maintenance ($2.9 million), refurbishment ($2.2 million), and augmentation ($1.8 million), partially offset by a $2.4 million decrease related to New Sites.

Latam

The 39.1% year-on-year decrease for the fourth quarter was primarily driven by decreases related to New Sites ($9.4 million), fiber business ($5.8 million), maintenance ($2.0 million) and other capital expenditure ($3.7 million).

MENA

The 86.0% year-on-year decrease for the fourth quarter was primarily due to a decrease related to New Sites ($0.6 million) and refurbishment ($0.1 million).

Results for the full ended December 31, 2024 versus 2023

Revenue

Revenue for the full year ended December 31, 2024 of $1,711.2 million declined 19.5% year-on-year driven primarily by the devaluation of the NGN versus the U.S. dollar. Organic revenue(1) increased by $1,021.7 million (increased 48.1%) year-on-year driven primarily by foreign exchange resets, power indexation, escalations, and continued growth in revenues from Tenants, Lease Amendments and New Sites. This growth was partially offset by the initial impact of the new financial terms in the renewed and extended contracts with MTN Nigeria, signed during the third quarter of 2024. Aggregate inorganic revenue declined $0.4 million, which related to the sixth stage of the Kuwait Acquisition, offset by the disposal of operations in Kuwait in December 2024 and Peru in April 2024. The increase in organic revenue was more than offset by the non-core impact of adverse movements in foreign exchange rates used to translate the results of foreign operations of $1,435.6 million, or 67.5%, of which $1,394.0 million was due to the devaluation of the NGN.

Refer to the revenue component of the segment results section of this discussion and analysis for further details.

(1) Refer to “Item 5. Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024 for the definition of organic revenue and additional information.

Adjusted EBITDA

Adjusted EBITDA was $928.4 million in the full year ended December 31, 2024, resulting in an Adjusted EBITDA margin of 54.3%. Adjusted EBITDA decreased 18.0% year-on-year reflecting the decrease in revenue described above, partially offset by a decrease in cost of sales, largely driven by the devaluation of the Naira versus the U.S. dollar. The reduction in cost of sales was primarily due to a decrease in tower repairs and maintenance costs ($42.9 million), power generation costs ($47.9 million), security services costs ($24.5 million), regulatory fees ($29.4 million) and staff costs ($8.7 million). The $59.1 million reduction in administrative costs included within Adjusted EBITDA was primarily driven by the devaluation of the Naira against the U.S. dollar, supported by cost saving initiatives implemented during the period.

Loss for the year

The year-on-year decrease in the loss for the year of $344.0 million is primarily driven by lower net financing costs of $321.9 million, as a result of a decrease in the unrealized net foreign exchange losses arising from financing linked to lower level of Naira devaluation year-on-year. This decrease is coupled with a net gain of $83.9 million from the Kuwait Disposal. In addition, there was reductions in impairment of property, plant and equipment, intangible assets excluding goodwill and related prepaid land rent of $72.9 million, primarily driven by power equipment assets in our SSA segment being classified as assets held for sale and remeasured at fair value less cost to sell in the third quarter of 2023, as well as decreases in depreciation ($69.2 million), power generation ($47.9 million), net impairment of withholding tax receivables ($46.9 million), tower repairs and maintenance ($42.9 million), regulatory fees ($29.4 million), and security services ($24.5 million). This was partially offset by an impairment of goodwill of $87.9 million related to the IHS Latam tower business which was recognized in the first quarter of 2024 and a decrease in revenue as described above.

Cash from operations

Cash from operations for the full year ended 2024 was $775.9 million, compared to $902.9 million for the full year ended 2023. The decrease reflects a decrease in operating income before working capital changes of $193.4 million, partially offset by an improvement in working capital movements of $66.3 million (inclusive of a withholding tax receivable decrease of $85.1 million).

ALFCF

ALFCF for the full year ended 2024 was $304.2 million, compared to $432.8 million for the full year ended 2023. The decrease in ALFCF was primarily due to the decrease in cash from operations before working capital movements of $193.4 million described above, an increase in net interest paid of $43.1 million, partially offset by a reduction in withholding tax of $32.5 million and maintenance and corporate capex of $69.6 million.

Project Green, which began in October 2022, resulted in annualized ALFCF savings of approximately $49 million (vs guidance of $51 million) for the full year ended 2024.

FINANCING ACTIVITIES DURING THE THREE MONTHS ENDED DECEMBER 31, 2024

Below is a summary of key facilities we have entered into, repaid or amended during the fourth quarter of 2024. Approximate U.S. dollar equivalent values for non-USD denominated facilities stated below are translated from the currency of the debt at the relevant exchange rates on December 31, 2024.

IHS Holding 2021 Notes Issuance

In November 2024, the 2026 Notes were partially redeemed, in an aggregate principal amount outstanding of $300.0 million following the issuance of the IHS Holding 2030/31 Notes and as of December 31, 2024, the aggregate principal amount outstanding on the IHS Holding 2026/28 Notes is $700.0 million.

IHS Holding (2022) Bullet Term Loan

In October 2024, the drawn amount of $430.0 million was fully prepaid using the proceeds received from the IHS Holding 2024 Dual-Tranche Term Loan.

IHS Holding (2024) Term Loan

In November 2024, the IHS Holding 2024 Term Loan was fully prepaid using the proceeds received from the IHS Holding 2030/31 Notes.

IHSHolding 2024 Dual-Tranche Term Loan

In October 2024, IHS Holding Limited entered into and drew down on a dual-tranche $255.0 million and ZAR 3,246.0 million loan agreement (together totaling approximately $427.6 million equivalent at December 31, 2024 exchange rates). This syndicated facility is scheduled to terminate in October 2029. The majority of the proceeds were applied toward the repayment of the IHS Holding (2022) Bullet Term Loan and general corporate purposes.

As of December 31, 2024, $427.6 million equivalent of the IHS Holding 2024 Dual-Tranche Term Loan was drawn down.

IHS Holding 2024 Notes Issuance

In November 2024, IHS Holding Limited issued $550.0 million 7.875% Senior Notes due 2030 (the “2030 Notes”) and $650.0 million 8.250% Senior Notes due 2031 (the “2031 Notes”, and together with the 2030 Notes, the “IHS Holding 2030/31 Notes”), guaranteed by IHS Netherlands Holdco B.V., IHS Netherlands NG1 B.V., IHS Netherlands NG2 B.V., Nigeria Tower Interco B.V., IHS Nigeria Limited, IHS Towers NG Limited, INT Towers Limited and INT Towers NG Finco 1 Plc.

The proceeds of the issuance of the IHS Holding 2030/31 Notes were used to partially redeem the principal amount of the 2026 Notes and 2027 Notes and fully prepay the IHS Holding (2024) Term Loan (including accrued and unpaid interest), fees and expenses related to the offering of the notes, and for general corporate purposes. The IHS Holding 2030/31 Notes pay interest semi-annually in arrear and the principal is repayable in full on maturity.

As of December 31, 2024, the aggregate principal amount outstanding of the IHS Holding 2030/31 Notes was $1,200.0 million.

IHS Netherlands Holdco B.V. Notes

In November 2024 and December 2024, the 2027 Notes were partially redeemed, in an aggregate principal amount outstanding of $654.0 million following the issuance of the IHS Holding 2030/31 Notes and as of December 31, 2024, the aggregate principal amount outstanding on the 2027 Notes was $286.0 million.

IHS Kuwait Facility

IHS Kuwait Limited was sold as part of the Kuwait Disposal that completed in December 2024.

IHS South Africa Overdraft

This overdraft facility, entered into in October 2023, expired in December 2024.

Letter of Credit Facilities

As of December 31, 2024, IHS Nigeria has utilized $2.0 million through funding under agreed letters of credit. These letters mature on March 31, 2025, and their interest rates range from 12.00% to 15.55%. These letters of credit are utilized to fund capital and operational expenditure with suppliers.

As of December 31, 2024, INT Towers Limited has utilized $4.8 million through funding under agreed letters of credit. These letters mature on March 31, 2025, and their interest rates range from 12.00% to 15.75%. These letters of credit are utilized to fund capital and operational expenditure with suppliers.

As of December 31, 2024, Global Independent Connect Limited has utilized $0.1 million through funding under agreed letters of credit. These letters mature on March 31, 2025, and their interest rates range from 15.25% to 15.28%. These letters of credit are utilized to fund capital and operational expenditure with suppliers.

OTHER ACTIVITIES AFTER REPORTING PERIOD

Oi S.A. Judicial Recovery Plan Update

On March 13, 2025, the Group acquired 100% of SPE Imóveis e Torres Selecionados as part of the Oi S.A. Judicial Recovery Plan. The acquisition effectively converts the 1,567 towers and 187 related land assets, already held by the Group as right-of use assets, to property, plant and equipment. The transaction was non-cash and was settled through discounts already given to Oi under the Judicial Recovery Plan agreed in April 2024.

Conference Call

IHS Towers will host a conference call on March 18, 2025, at 8:30am ET to review its financial and operating results. Supplemental materials will be available on the Company’s website, www.ihstowers.com. The conference call can be accessed by calling +1 646 233 4753 (U.S./Canada) or +44 20 3936 2999 (UK/International). The call ID is 519217.

A simultaneous webcast and replay will be available in the Investor Relations section of the Company’s website, www.ihstowers.com, on the Earnings Materials page.

Upcoming Conferences and Events

IHS Towers management is expected to participate in the upcoming conferences outlined below, dates noted are subject to change. Visit www.ihstowers.com/investors/investor-presentations-events for additional conferences information.

  • Avior 2025 Corporate Summit (South Africa) – March 25, 2025

About IHS Towers

IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count and is solely focused on the emerging markets. The Company has over 39,000 towers across its nine markets, including Brazil, Cameroon, Colombia, Côte d’Ivoire, Egypt, Nigeria, Rwanda, South Africa and Zambia. For more information, please email: [email protected] or visit: www.ihstowers.com.

For more information about the Company and our financial and operating results, please also refer to the 4Q24 Supplemental Information deck posted to our Investors Relations website at www.ihstowers.com/investors.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. We intend such forward-looking statements to be covered by relevant safe harbor provisions for forward-looking statements (or their equivalent) of any applicable jurisdiction, including those contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this press release may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecast,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this press release include, but are not limited to statements regarding our future results of operations and financial position, future organic growth, anticipated results for the fiscal year 2025 (including our ability to enhance profitability and cash flow generation) industry and business trends, business strategy and plans, shareholder value creation (including our ongoing strategic review and related productivity enhancements and cost reductions, as well as our ability to refinance or meet our debt obligations), our market growth, position and our objectives for future operations, including our ability to maintain relationships with customers, the potential benefit of the terms of our contract renewals the impact (illustrative or otherwise) of the renewed agreements with MTN Nigeria (including certain rebased fee components) on our financial results, the impact of currency and exchange rate fluctuations (including the fluctuations of the Naira) and other economic and geopolitical factors on our future results and operations, the outcome and potential benefit of our ongoing strategic review, including our ability to make commercial progress, increase Adjusted EBITDA and cash flow generation and reduce debt, our objectives for future operations, our participation in upcoming presentations and events, and the timing of any of the foregoing.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to:

  • non-performance under or termination, non-renewal or material modification of our customer agreements;
  • volatility in terms of timing for settlement of invoices or our inability to collect amounts due under invoices;
  • a reduction in the creditworthiness and financial strength of our customers;
  • the business, legal and political risks in the countries in which we operate;
  • general macroeconomic conditions in the countries in which we operate;
  • changes to existing or new tax laws, rates or fees;
  • foreign exchange risks, particularly in relation to the Nigerian Naira, and/or ability to hedge against such risks in our commercial agreements or to access U.S. dollars in our markets;
  • the effect of regional or global health pandemics, geopolitical conflicts and wars and acts of terrorism including, but not limited to, or as a result of, political instability, religious differences, ethnicity and regionalism in emerging and less developed markets;
  • our inability to successfully execute our business strategy and operating plans, including our ability to increase the number of Colocations and Lease Amendments on our Towers and construct New Sites or develop business related to adjacent telecommunications verticals (including, for example, relating to our fiber businesses in Latin America and elsewhere) or deliver on our sustainability or environmental, social and governance (ESG) strategy and initiatives under anticipated costs, timelines, and complexity, such as our Carbon Reduction Roadmap (and Project Green);
  • our inability to manage growth;
  • our reliance on third-party contractors or suppliers, including failure, underperformance or inability to provide products or services to us (in a timely manner or at all) due to sanctions regulations, supply chain issues or for other reasons;
  • our estimates and assumptions and estimated operating results may differ materially from actual results;
  • increases in operating expenses, including fluctuating costs for diesel or ground leases;
  • failure to renew or extend our ground leases, or protect our rights to access and operate our Towers or other telecommunications infrastructure assets;
  • loss of tenancies or customers;
  • risks related to our indebtedness;
  • changes to the network deployment plans of mobile operators in the countries in which we operate;
  • a reduction in demand for our services;
  • the introduction of new technology reducing the need for tower infrastructure and/or adjacent telecommunication verticals;
  • an increase in competition in the telecommunications tower infrastructure industry and/or adjacent telecommunication verticals;
  • our failure to integrate recent or future acquisitions;
  • the identification by management of material weaknesses in our internal control over financial reporting, which could affect our ability to produce accurate financial statements on a timely basis or cause us to fail to meet our future reporting obligations;
  • increased costs, harm to reputation, or other adverse impacts related to increased intention to and evolving expectations for environmental, social and governance initiatives;
  • our reliance on our senior management team and/or key employees;
  • failure to obtain required approvals and licenses for some of our sites or businesses or comply with applicable regulations;
  • inability to raise financing to fund future growth opportunities or operating expense reduction strategies;
  • environmental liability;
  • inadequate insurance coverage, property loss and unforeseen business interruption;
  • compliance with or violations (or alleged violations) of laws, regulations and sanctions, including but not limited to those relating to telecommunications regulatory systems, tax, labor, employment (including new minimum wage regulations), unions, health and safety, antitrust and competition, environmental protection, consumer protection, data privacy and protection, import/export, foreign exchange or currency, and of anti-bribery, anti-corruption and/or money laundering laws, sanctions and regulations;
  • disruptions in our supply of diesel or other materials, as well as related price fluctuations;
  • legal and arbitration proceedings;
  • our reliance on shareholder support (including to invest in growth opportunities) and related party transaction risks;
  • risks related to the markets in which we operate, including but not limited to local community opposition to some of our sites or infrastructure, and the risks from our investments into emerging and other less developed markets;
  • injury, illness or death of employees, contractors or third parties arising from health and safety incidents;
  • loss or damage of assets due to security issues or civil commotion;
  • loss or damage resulting from attacks on any information technology system or software;
  • loss or damage of assets due to extreme weather events whether or not due to climate change;
  • failure to meet the requirements of accurate and timely financial reporting and/or meet the standards of internal control over financial reporting that support a clean certification under the Sarbanes Oxley Act;
  • risks related to our status as a foreign private issuer; and
  • the important factors discussed in the section titled “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024.

The forward-looking statements in this press release are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. You should read this press release and the documents that we reference in this press release with the understanding that our actual future results, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Additionally, we may provide information herein that is not necessarily “material” under the federal securities laws for SEC reporting purposes, but that is informed by various ESG standards and frameworks (including standards for the measurement of underlying data), and the interests of various stakeholders. Particularly in the ESG context, materiality is subject to various definitions that often differ from, and are generally more expansive than, the definition under US federal securities laws. Much of this information is subject to assumptions, estimates or third-party information that is still evolving and subject to change. For example, we note that standards and expectations regarding greenhouse gas (GHG) accounting and the processes for measuring and counting GHG emissions and GHG emissions reductions are evolving, and it is possible that our approaches both to measuring our emissions and any reductions may be at some point, either currently or in future, considered by certain parties to not be in keeping with best practices. In addition, our disclosures based on any standards may change due to revisions in framework requirements, availability of information, changes in our business or applicable government policies, or other factors, some of which may be beyond our control. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not assume, and expressly disclaim, any obligation to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise. Additionally, references to our website and other documents contained in this press release are provided for convenience only, and their content is not incorporated by reference into this press release.

IHS HOLDING LIMITED

CONDENSED CONSOLIDATED STATEMENT OF INCOME/(LOSS) AND OTHER COMPREHENSIVE (LOSS)/INCOME

FOR THE THREE MONTHS AND FULL YEAR ENDED DECEMBER 31, 2024 AND 2023:

 

 

 

 

 

 

 

 

 

 

 

Three months ended December 31,

 

Full year ended December 31,

 

 

2024

 

2023

 

2024

 

2023

 

 

$’000

 

$’000

 

$’000

 

$’000

 

 

 

 

 

 

 

 

 

Revenue

 

437,822

 

509,784

 

1,711,225

 

2,125,539

Cost of sales

 

(227,788)

 

(220,678)

 

(890,533)

 

(1,183,306)

Administrative expenses

 

(82,260)

 

(112,906)

 

(429,818)

 

(404,783)

(Net loss allowance)/net reversal of loss on trade receivables

 

(2,082)

 

(1,977)

 

25

 

(7,202)

Other income

 

86,592

 

35

 

88,248

 

404

Operating income

 

212,284

 

174,258

 

479,147

 

530,652

Finance income

 

175,716

 

8,420

 

33,747

 

25,209

Finance costs

 

(151,646)

 

(621,091)

 

(2,123,138)

 

(2,436,511)

Income/(loss) before income tax

 

236,354

 

(438,413)

 

(1,610,244)

 

(1,880,650)

Income tax expense

 

6,712

 

(18,410)

 

(33,957)

 

(107,528)

Income/(loss) for the period

 

243,066

 

(456,823)

 

(1,644,201)

 

(1,988,178)

 

 

 

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

 

 

 

Owners of the Company

 

246,515

 

(453,588)

 

(1,632,025)

 

(1,976,609)

Non-controlling interests

 

(3,449)

 

(3,235)

 

(12,176)

 

(11,569)

Income/(loss) for the period

 

243,066

 

(456,823)

 

(1,644,201)

 

(1,988,178)

 

 

 

 

 

 

 

 

 

Income/(loss) per share ($) – basic

 

0.74

 

(1.36)

 

(4.90)

 

(5.93)

Income/(loss) per share ($) – diluted

 

0.73

 

(1.36)

 

(4.90)

 

(5.93)

 

 

 

 

 

 

 

 

 

Other comprehensive income:

 

 

 

 

 

 

 

 

Items that may be reclassified to income or loss

 

 

 

 

 

 

 

 

Exchange gain recycled to income statement on disposal of subsidiary

 

(98)

 

 

(98)

 

Exchange differences on translation of foreign operations

 

(267,515)

 

336,006

 

996,548

 

970,808

Other comprehensive (loss)/income for the period, net of taxes

 

(267,613)

 

336,006

 

996,450

 

970,808

 

 

 

 

 

 

 

 

 

Total comprehensive loss for the period

 

(24,547)

 

(120,817)

 

(647,751)

 

(1,017,370)

 

 

 

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

 

 

 

Owners of the Company

 

(21)

 

(129,142)

 

(592,196)

 

(1,025,754)

Non-controlling interests

 

(24,526)

 

8,325

 

(55,555)

 

8,384

Total comprehensive loss for the period

 

(24,547)

 

(120,817)

 

(647,751)

 

(1,017,370)

IHS HOLDING LIMITED

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

FOR THE FULL YEAR ENDED DECEMBER 31, 2024 AND 2023:

 

 

 

 

 

 

 

2024

 

2023

 

 

$’000

 

$’000

Non-current assets

 

 

 

 

Property, plant and equipment

 

1,352,645

 

1,740,235

Right-of-use assets

 

699,057

 

886,909

Goodwill

 

403,242

 

619,298

Other intangible assets

 

673,952

 

933,030

Deferred income tax assets

 

73,345

 

63,786

Derivative financial instrument assets

 

29,410

 

1,540

Trade and other receivables

 

121,033

 

147,305

 

 

3,352,684

 

4,392,103

Current assets

 

 

 

 

Inventories

 

30,746

 

40,589

Income tax receivable

 

2,250

 

3,755

Derivative financial instrument assets

 

 

565

Trade and other receivables

 

313,356

 

607,835

Cash and cash equivalents

 

577,956

 

293,823

Assets held for sale

 

 

26,040

 

 

924,308

 

972,607

 

 

 

 

 

TOTAL ASSETS

 

4,276,992

 

5,364,710

 

 

 

 

 

Non-current liabilities

 

 

 

 

Trade and other payables

 

5,218

 

4,629

Borrowings

 

3,219,215

 

3,056,696

Lease liabilities

 

470,476

 

510,838

Provisions for other liabilities and charges

 

83,876

 

86,131

Deferred income tax liabilities

 

100,450

 

137,106

 

 

3,879,235

 

3,795,400

Current liabilities

 

 

 

 

Trade and other payables

 

422,500

 

532,627

Provisions for other liabilities and charges

 

182

 

277

Derivative financial instrument liabilities

 

10,203

 

68,133

Income tax payable

 

49,879

 

75,612

Borrowings

 

128,734

 

454,151

Lease liabilities

 

82,068

 

91,156

 

 

693,566

 

1,221,956

 

 

 

 

 

TOTAL LIABILITIES

 

4,572,801

 

5,017,356

 

 

 

 

 

Stated capital

 

5,403,139

 

5,394,812

Accumulated losses

 

(6,925,419)

 

(5,293,394)

Other reserves

 

1,067,701

 

8,430

Equity attributable to owners of the Company

 

(454,579)

 

109,848

Non-controlling interests

 

158,770

 

237,506

TOTAL EQUITY

 

(295,809)

 

347,354

 

 

 

 

 

TOTAL LIABILITIES AND EQUITY

 

4,276,992

 

5,364,710

IHS HOLDING LIMITED

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE FULL YEAR ENDED DECEMBER 31, 2024 AND 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to owners of the Company

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-

 

 

 

 

Stated

 

Accumulated

 

Other

 

 

 

controlling

 

Total

 

 

capital

 

losses

 

reserves

 

Total

 

interests

 

Equity

 

 

$’000

 

$’000

 

$’000

 

$’000

 

$’000

 

$’000

 

 

 

 

 

 

 

 

 

 

 

 

 

At January 1, 2023

 

5,311,953

 

 

(3,317,652

)

 

(861,271

)

 

1,133,030

 

 

227,200

 

 

1,360,230

 

Shares repurchased and canceled through buyback program

 

(10,037

)

 

 

 

 

 

(10,037

)

 

 

 

(10,037

)

Non-controlling interests arising on business combination

 

 

 

 

 

 

 

 

 

1,922

 

 

1,922

 

Exercise of share options

 

92,896

 

 

 

 

(92,896

)

 

 

 

 

 

 

Share-based payment expense

 

 

 

 

 

13,168

 

 

13,168

 

 

 

 

13,168

 

Other reclassifications related to share-based payment

 

 

 

867

 

 

(1,426

)

 

(559

)

 

 

 

(559

)

Total transactions with owners

 

82,859

 

 

867

 

 

(81,154

)

 

2,572

 

 

1,922

 

 

4,494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the year

 

 

 

(1,976,609

)

 

 

 

(1,976,609

)

 

(11,569

)

 

(1,988,178

)

Other comprehensive income

 

 

 

 

 

950,855

 

 

950,855

 

 

19,953

 

 

970,808

 

Total comprehensive (loss)/income

 

 

 

(1,976,609

)

 

950,855

 

 

(1,025,754

)

 

8,384

 

 

(1,017,370

)

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2023

 

5,394,812

 

 

(5,293,394

)

 

8,430

 

 

109,848

 

 

237,506

 

 

347,354

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At January 1, 2024

 

5,394,812

 

 

(5,293,394

)

 

8,430

 

 

109,848

 

 

237,506

 

 

347,354

 

Non-controlling interests derecognized on disposal

 

 

 

 

 

 

 

 

 

(23,181

)

 

(23,181

)

Exercise of share options

 

8,327

 

 

 

 

(8,327

)

 

 

 

 

 

 

Share-based payment expense

 

 

 

 

 

27,769

 

 

27,769

 

 

 

 

27,769

 

Total transactions with owners

 

8,327

 

 

 

 

19,442

 

 

27,769

 

 

(23,181

)

 

4,588

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the year

 

 

 

(1,632,025

)

 

 

 

(1,632,025

)

 

(12,176

)

 

(1,644,201

)

Other comprehensive income/(loss), net of recycling

 

 

 

 

 

1,039,829

 

 

1,039,829

 

 

(43,379

)

 

996,450

 

Total comprehensive (loss)/income

 

 

 

(1,632,025

)

 

1,039,829

 

 

(592,196

)

 

(55,555

)

 

(647,751

)

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2024

 

5,403,139

 

 

(6,925,419

)

 

1,067,701

 

 

(454,579

)

 

158,770

 

 

(295,809

)

IHS HOLDING LIMITED

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE THREE MONTHS AND FULL YEAR ENDED DECEMBER 31, 2024 AND 2023:

 

 

 

 

 

 

 

 

 

 

 

Three months ended December 31,

 

Full year ended December 31,

 

 

2024

 

2023

 

2024

 

2023

 

 

$’000

 

$’000

 

$’000

 

$’000

Cash flows from operating activities

 

 

 

 

 

 

 

 

Cash from operations

 

348,845

 

 

162,054

 

 

775,856

 

 

902,923

 

Income taxes paid

 

(3,538

)

 

(3,004

)

 

(38,629

)

 

(45,411

)

Payment for rent

 

(956

)

 

431

 

 

(7,827

)

 

(3,716

)

Payment for tower and tower equipment decommissioning

 

(43

)

 

(16

)

 

(95

)

 

(343

)

Net cash from operating activities

 

344,308

 

 

159,465

 

 

729,305

 

 

853,453

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

(61,460

)

 

(81,441

)

 

(235,169

)

 

(464,897

)

Payment in advance for property, plant and equipment

 

(14,283

)

 

(22,145

)

 

(29,864

)

 

(111,065

)

Purchase of software and licenses

 

(689

)

 

(3,141

)

 

(3,980

)

 

(22,811

)

Consideration paid on business combinations, net of cash acquired

 

 

 

 

 

 

 

(4,486

)

Proceeds from sale of subsidiaries, net of cash disposed

 

114,887

 

 

 

 

118,960

 

 

 

Proceeds from disposal of property, plant and equipment

 

11,707

 

 

1,451

 

 

26,706

 

 

2,919

 

Insurance claims received

 

22

 

 

11

 

 

73

 

 

321

 

Interest received

 

5,809

 

 

7,670

 

 

18,660

 

 

25,008

 

Deposit of short-term deposits

 

(3,070

)

 

4,538

 

 

(43,660

)

 

(183,400

)

Refund of short-term deposits

 

2,736

 

 

(469

)

 

211,453

 

 

36,162

 

Net cash from/(used in) investing activities

 

55,659

 

 

(93,526

)

 

63,179

 

 

(722,249

)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Shares repurchased and canceled through buyback program

 

 

 

(4,324

)

 

 

 

(10,037

)

Proceeds received from issuance of borrowings (net of transaction costs)

 

1,596,978

 

 

9,660

 

 

2,208,375

 

 

986,604

 

Repayment of borrowings

 

(1,683,484

)

 

(45,349

)

 

(2,149,307

)

 

(689,940

)

Fees on borrowings and derivative instruments

 

(1,263

)

 

(4,621

)

 

(10,558

)

 

(19,441

)

Interest paid

 

(73,983

)

 

(74,911

)

 

(326,984

)

 

(299,029

)

Payment for the principal portion of lease liabilities

 

(10,770

)

 

(13,428

)

 

(55,233

)

 

(72,854

)

Interest paid for lease liabilities

 

(19,495

)

 

(17,744

)

 

(66,041

)

 

(58,443

)

Interest/premium paid on derivative instruments

 

(8,834

)

 

 

 

(8,834

)

 

 

Net gain/(loss) settled on derivative instruments

 

157

 

 

222

 

 

(22,414

)

 

839

 

Net cash (used in)/from financing activities

 

(200,694

)

 

(150,495

)

 

(430,996

)

 

(162,301

)

 

 

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

199,273

 

 

(84,556

)

 

361,488

 

 

(31,097

)

Cash and cash equivalents at beginning of year

 

397,499

 

 

425,436

 

 

293,823

 

 

514,078

 

Exchange differences

 

(18,816

)

 

(47,057

)

 

(77,355

)

 

(189,158

)

Cash and cash equivalents at end of period

 

577,956

 

 

293,823

 

 

577,956

 

 

293,823

 

Use of Non-IFRS financial measures

Certain parts of this document contain non-IFRS financial measures, including Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Levered Free Cash Flow (“ALFCF”). The non-IFRS financial information is presented for supplemental informational purposes only and should not be considered a substitute for financial information presented in accordance with Accounting Standards as issued by International Accounting Standards Board (“IFRS® Accounting Standards”), and may be different from similarly titled non-IFRS measures used by other companies.

Adjusted EBITDA and Adjusted EBITDA Margin

We define Adjusted EBITDA (including by segment) as (loss)/income for the period, before income tax expense/(benefit), finance costs and income, depreciation and amortization, net impairment/(reversal of impairment) of withholding tax receivables, impairment of goodwill, business combination transaction costs, net impairment/(reversal of impairment) of property, plant and equipment, intangible assets excluding goodwill and related prepaid land rent, reversal of provision for decommissioning costs, net (gain)/loss on sale of assets, share-based payment (credit)/expense, insurance claims, gain on disposal of subsidiary and certain other items that management believes are not indicative of the core performance of our business.

We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue for the applicable period, expressed as a percentage.

We believe Adjusted EBITDA and Adjusted EBITDA Margin are useful to investors and are used by our management for measuring profitability and allocating resources, because they exclude the impact of certain items that have less bearing on our core operating performance such as interest expense and taxes. We believe that utilizing Adjusted EBITDA and Adjusted EBITDA Margin allows for a more meaningful comparison of operating fundamentals between companies within our industry by eliminating the impact of capital structure and taxation differences between the companies.

Adjusted EBITDA measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to us, many of which present an Adjusted EBITDA-related performance measure when reporting their results.

Adjusted EBITDA and Adjusted EBITDA Margin are used by different companies for differing purposes and are often calculated in ways that reflect the circumstances of those companies. You should exercise caution in comparing Adjusted EBITDA and Adjusted EBITDA Margin as reported by us to Adjusted EBITDA and Adjusted EBITDA Margin as reported by other companies. Adjusted EBITDA and Adjusted EBITDA Margin are unaudited and have not been prepared in accordance with IFRS Accounting Standards.

Adjusted EBITDA and Adjusted EBITDA Margin are not measures of performance under IFRS Accounting Standards and you should not consider these as an alternative to (loss)/income or (loss)/income margin for the period or other financial measures determined in accordance with IFRS Accounting Standards.

Adjusted EBITDA and Adjusted EBITDA Margin have limitations as analytical tools, and you should not consider them in isolation. Some of these limitations are:

  • they do not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our indebtedness;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often need to be replaced in the future and Adjusted EBITDA and Adjusted EBITDA Margin do not reflect any cash requirements that would be required for such replacements;
  • some of the items we eliminate in calculating Adjusted EBITDA and Adjusted EBITDA Margin reflect cash payments that have less bearing on our core operating performance, but that impact our operating results for the applicable period; and
  • the fact that other companies in our industry may calculate Adjusted EBITDA and Adjusted EBITDA Margin differently than we do, which limits their usefulness as comparative measures.

Accordingly, investors and prospective investors should not place undue reliance on Adjusted EBITDA or Adjusted EBITDA Margin.

ALFCF

We define ALFCF as cash from operations, before certain items of income or expenditure that management believes are not indicative of the core cash flow of our business (to the extent that these items of income and expenditure are included within cash flow from operating activities), and after taking into account net working capital movements, income taxes paid, withholding tax, lease and rent payments made, net interest paid or received, business combination transaction costs, maintenance capital expenditure and routine corporate capital expenditure. We believe that it is important to measure the free cash flows we have generated from operations, after accounting for the cash cost of funding and routine capital expenditure required to generate those cash flows.

We believe ALFCF is useful to investors because it is also used by our management for measuring our operating cash flow, liquidity and allocating resources. While Adjusted EBITDA provides management with a basis for assessing its current operating performance, we use ALFCF in order to assess the long-term, sustainable operating liquidity of our business. ALFCF is derived through an understanding of the funds generated from operations, taking into account our capital structure and the taxation environment (including withholding tax implications), as well as the impact of non-discretionary maintenance capital expenditure and routine corporate capital expenditure. ALFCF provides management with a metric through which to measure the underlying cash generation of the business by further adjusting for expenditure that are non-discretionary in nature (such as interest paid and income taxes paid), as well as certain cash items that impact cash from operations in any particular period.

ALFCF and similar measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to us, many of which present an ALFCF-related measure when reporting their results. Such measures are used in the telecommunications infrastructure sector as they are seen to be important in assessing the liquidity of a business. We present ALFCF to provide investors with a meaningful measure for comparing our liquidity to those of other companies, particularly those in our industry.

ALFCF and similar measures are used by different companies for differing purposes and are often calculated in ways that reflect the circumstances of those companies. You should exercise caution in comparing ALFCF as reported by us to ALFCF or similar measures as reported by other companies. ALFCF is unaudited and has not been prepared in accordance with IFRS Accounting Standards.

ALFCF is not intended to replace cash from operations for the period or any other measures of cash flow under IFRS Accounting Standards.

ALFCF has limitations as an analytical tool, and you should not consider it in isolation. Some of these limitations are:

  • not all cash changes are reflected, for example, changes in working capital are not included and discretionary capital expenditure are not included;
  • some of the items that we eliminate in calculating ALFCF reflect cash payments that have less bearing on our liquidity, but that impact our operating results for the applicable period;
  • the fact that certain cash charges, such as lease payments made, can include payments for multiple future years that are not reflective of operating results for the applicable period, which may result in lower lease payments for subsequent periods;
  • the fact that other companies in our industry may have different capital structures and applicable tax regimes, which limits its usefulness as a comparative measure; and
  • the fact that other companies in our industry may calculate ALFCF differently than we do, which limits their usefulness as comparative measures.

Accordingly, you should not place undue reliance on ALFCF.

Reconciliation from income/(loss) for the period to Adjusted EBITDA and Adjusted EBITDA Margin

The following is a reconciliation of Adjusted EBITDA and Adjusted EBITDA margin to the most directly comparable IFRS measure which are income/(loss) and income/(loss) margin, respectively, for the three and twelve months ended December 31, 2024 and 2023:

 

 

 

 

 

 

 

 

 

 

 

Three months ended December 31,

 

For the full year ended December 31,

 

 

2024

 

2023

 

2024

 

2023

 

 

$’000

 

$’000

 

$’000

 

$’000

 

 

 

 

 

 

 

 

 

Income/(loss) for the year

 

243,066

 

 

(456,823

)

 

(1,644,201

)

 

(1,988,178

)

Divided by: Total revenue

 

437,822

 

 

509,784

 

 

1,711,225

 

 

2,125,539

 

Income/(loss) margin for the year

 

55.5

%

 

(89.6

)%

 

(96.1

)%

 

(93.5

)%

Adjustments:

 

 

 

 

 

 

 

 

Income tax expense

 

(6,712

)

 

18,410

 

 

33,957

 

 

107,528

 

Finance costs(a)

 

151,646

 

 

621,091

 

 

2,123,138

 

 

2,436,511

 

Finance income(a)

 

(175,716

)

 

(8,420

)

 

(33,747

)

 

(25,209

)

Depreciation and amortization

 

96,695

 

 

95,205

 

 

362,735

 

 

435,586

 

Net (impairment reversal)/impairment of withholding tax receivables(b)

 

(31,746

)

 

12,880

 

 

1,081

 

 

47,992

 

Impairment of goodwill

 

 

 

 

 

87,894

 

 

 

Business combination transaction costs

 

322

 

 

785

 

 

1,280

 

 

2,432

 

Net impairment/(reversal of impairment) of property, plant and equipment, intangible assets excluding goodwill and related prepaid land rent(c)

 

4,692

 

 

(20,814

)

 

17,651

 

 

87,696

 

Gain/(loss) on disposal of property, plant and equipment

 

23,725

 

 

(2,854

)

 

20,163

 

 

(3,806

)

Share-based payment expense(d)

 

18,061

 

 

3,799

 

 

27,940

 

 

13,370

 

Insurance claims(e)

 

(22

)

 

(11

)

 

(73

)

 

(321

)

Gain on disposal of subsidiary

 

(83,838

)

 

 

 

(83,838

)

 

 

Other costs(f)

 

6,199

 

 

10,958

 

 

14,374

 

 

19,017

 

Other income

 

 

 

(24

)

 

 

 

(83

)

Adjusted EBITDA

 

246,372

 

 

274,182

 

 

928,354

 

 

1,132,535

 

Divided by: Total revenue

 

437,822

 

 

509,784

 

 

1,711,225

 

 

2,125,539

 

Adjusted EBITDA Margin

 

56.3

%

 

53.8

%

 

54.3

%

 

53.3

%

 
(a) Finance costs consist of interest expense and loan facility fees on borrowings, the unwinding of the discount on our decommissioning liability and lease liability, realized and unrealized net foreign exchange losses arising from financing arrangements and net realized and unrealized losses from valuations of financial instruments. Finance income consists of interest income from bank deposits, realized and unrealized net foreign exchange gains arising from financing arrangements and net realized and unrealized gains from valuations of financial instruments.
(b) Withholding tax primarily represents amounts withheld by customers in Nigeria and paid to the local tax authority. The amounts withheld may be recoverable in settlement of future corporate income tax liabilities in the relevant operating company. Withholding tax receivables are reviewed for recoverability at each reporting period end and impaired if not forecast to be recoverable.
(c) Represents non-cash charges related to the impairment of property, plant and equipment, intangible assets excluding goodwill and related prepaid land rent on the decommissioning of sites.
(d) Relates to share-based compensation expenses which are non-cash and vary from period to period depending on timing of awards and changes to valuation inputs assumptions.
(e) Represents insurance claims included as non-operating income.
(f) Other costs included one-off expenses related to strategic initiatives and operating systems of $10.8 million, costs related to internal reorganization of $2.7 million and one-off professional fees related to financing of $0.8 million.

Reconciliation from cash from operations to ALFCF

The following is a reconciliation of ALFCF to the most directly comparable IFRS measure, which is cash from operations, for the three and twelve months ended December 31, 2024 and 2023:

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended December 31,

 

For the full year ended December 31,

 

 

 

2024

 

2023

 

2024

 

2023

 

 

 

$’000

 

$’000

 

$’000

 

$’000

 

 

 

 

 

 

 

 

 

 

 

Cash from operations

 

348,845

 

 

162,054

 

 

775,856

 

 

902,923

 

 

Net movement in working capital

 

(92,104

)

 

104,002

 

 

158,667

 

 

224,982

 

 

Income taxes paid

 

(3,538

)

 

(3,004

)

 

(38,629

)

 

(45,411

)

 

Withholding tax(a)

 

(20,777

)

 

(27,473

)

 

(85,076

)

 

(117,561

)

 

Lease and rent payments made

 

(31,221

)

 

(30,741

)

 

(129,101

)

 

(135,013

)

 

Net interest paid(b)

 

(77,008

)

 

(67,241

)

 

(317,158

)

 

(274,021

)

 

Business combination costs

 

4,857

 

 

2,356

 

 

6,707

 

 

6,792

 

 

Other costs(c)

 

1,734

 

 

4,482

 

 

5,513

 

 

12,229

 

 

Maintenance capital expenditure(d)

 

(23,284

)

 

(25,680

)

 

(71,796

)

 

(139,958

)

 

Corporate capital expenditures(e)

 

(383

)

 

(590

)

 

(785

)

 

(2,180

)

 

ALFCF

 

107,121

 

 

118,165

 

 

304,198

 

 

432,782

 

 

 

 

 

 

 

 

 

 

 

 

Non-controlling interests

 

(2,084

)

 

(2,113

)

 

(12,411

)

 

(9,860

)

 

ALFCF excluding non-controlling interests

 

105,037

 

 

116,052

 

 

291,787

 

 

422,922

 

 

 
(a) Withholding tax primarily represents amounts withheld by customers which may be recoverable through an offset against future corporate income tax liabilities in the relevant operating company.
(b) Represents the aggregate value of interest paid and interest income received.
(c) Other costs for the years ended December 31, 2024 and 2023, primarily related to one-off consulting fees.
(d) We incur capital expenditure in relation to the maintenance of our towers and fiber equipment, which is non-discretionary in nature and required in order for us to optimally run our portfolio and to perform in line with our service level agreements with customers. Maintenance capital expenditure includes the periodic repair, refurbishment and replacement of tower, fiber equipment and power equipment at existing sites to keep such assets in service.
(e) Corporate capital expenditure, which are non-discretionary in nature, consist primarily of routine spending on information technology infrastructure.

 

For more information, please email: [email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Networks Mobile/Wireless Technology Carriers and Services Telecommunications

MEDIA:

Voting Begins for Trump Media Annual Meeting

TMTG Files Definitive Proxy Statement

SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq: DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, announced that it filed its definitive proxy statement today with the U.S. Securities and Exchange Commission for the Company’s annual meeting scheduled for 9:00 a.m. Eastern time on April 30, 2025 and shareholders may begin online voting today on the proposals to be presented at the annual meeting.

Among other proposals, TMTG stockholders will have the opportunity to vote on a proposal to reincorporate the Company to Florida, where TMTG has its principal place of business.

TMTG CEO and Chairman Devin Nunes said, “We’re looking forward to TMTG’s annual meeting and encourage all shareholders to participate. We’re particularly enthusiastic for shareholders to vote on reincorporating Trump Media in Florida, as the Company fulfills its growth strategy, including possible mergers, acquisitions, and other partnerships.”

TMTG shareholders can find more information on how to vote and how to participate in the annual meeting at proxydocs.com/djt.

Cautionary Statement About Forward-Looking Statements

This press release includes forward-looking statements regarding, among other things, the plans, strategies, and prospects of TMTG. We have based these forward-looking statements on our current expectations about future events. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by, or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “soon,” “goal,” “intends,” or similar expressions. Forward-looking statements are not guarantees of future performance, and involve risks, uncertainties and assumptions that may cause our actual results to differ materially from the expectations that we describe in our forward-looking statements. There may be events in the future that we are not accurately able to predict, or over which we have no control.

Additional Information and Where to Find It

The Company has filed a Definitive Proxy Statement on Schedule 14A with the Securities and Exchange Commission (the “SEC”) on March 18, 2025 (the “Proxy Statement”) as well as other relevant materials with respect to the Company’s solicitation of proxies for the annual meeting of stockholders expected to be held on April 30, 2025 (the “Annual Meeting”). INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT MATERIALS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION. The Proxy Statement and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC at the Company’s website, https://www.ir.tmtgcorp.com, or by requesting them in writing or by telephone from us at 401 N. Cattlemen Road, Suite 200, Sarasota Florida 34232.

Participants

The Company and its directors and executive officers will be participants in the solicitation of proxies with respect to a solicitation by the Company. Information about those executive officers and directors of the Company and their ownership of the Company’s common stock is set forth in the Proxy Statement. Investors and security holders may obtain additional information regarding direct and indirect interests of the Company and its executive officers and directors in the matters to be voted upon at the Annual Meeting by reading the Preliminary Proxy Statement. These documents are or will be available free of charge at the SEC’s website at www.sec.gov.

About TMTG

The mission of TMTG is to end Big Tech’s s assault on free speech by opening up the Internet and giving people their voices back. TMTG operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations, as well as Truth+, a TV streaming platform focusing on family-friendly live TV channels and on-demand content. TMTG is also launching Truth.Fi, a financial services and FinTech brand incorporating America First investment vehicles.

Investor Relations Contact

Shannon Devine (MZ Group | Managing Director – MZ North America)
Email: [email protected]

Media Contact


[email protected]